Table 3.
Characteristics and non-oral irAEs in the matched patients with and without oral irAEs.
| Characteristics | Oral irAE (n = 153) | No oral irAE (n = 153) | OR (95% CI) | P |
|---|---|---|---|---|
| Age, years | 67.1 ± 10.8 | 66.7 ± 10.4 | — | .685 |
| Female | 58 (37.9) | 58 (37.9) | — | — |
| Immune checkpoint inhibitor regimen (%) | ||||
| Pembrolizumab | 69 (45.1) | 69 (45.1) | — | — |
| Nivolumab | 51 (33.3) | 51 (33.3) | — | — |
| Ipilimumab + Nivolumab | 16 (10.5) | 16 (10.5) | — | — |
| Ipilimumab + Pembrolizumab | 6 (3.9) | 6 (3.9) | — | — |
| Atezumab | 5 (3.3) | 5 (3.3) | — | — |
| Ipilimumab + Nivolumab + Pembrolizumab | 3 (2.0) | 3 (2.0) | — | — |
| Other regimens | 3 (2.0) | 3 (2.0) | — | — |
| Number of infusions (IQR) | 7 (2.5, 16) | 7 (3, 15.5) | — | 0.923 |
| Treatment duration days (IQR) | 147 (29, 363) | 123 (28.5, 335) | — | 0.633 |
| Type of non-oral irAE (%) | ||||
| Mucosal disorder | 46 | — | — | — |
| Xerostomia | 109 | — | — | — |
| Dysgeusia | 27 | — | — | — |
| Type of non-oral irAE (%) | — | — | ||
| Any | 104 (68.0) | 83 (54.2) | 1.79 (1.12, 2.85) | 0.014 |
| Cutaneous | 53 (34.6) | 36 (23.5) | 1.72 (1.04, 2.84) | 0.032 |
| Gastrointestinal | 34 (22.2) | 30 (19.6) | 1.17 (0.67, 2.03) | 0.574 |
| Pulmonary | 25 (16.3) | 20 (13.1) | 1.30 (0.69, 2.45) | 0.419 |
| Rheumatological | 23 (15.0) | 13 (8.5) | 1.91 (0.93, 3.92) | 0.076 |
| Thyroid | 16 (10.5) | 6 (3.9) | 2.86 (1.09, 7.52) | 0.027 |
| Hepatic | 11 (7.2) | 9 (5.9) | 1.24 (0.5, 3.08) | 0.644 |
| Neurologic | 10 (6.5) | 6 (3.9) | 1.71 (0.61, 4.84) | 0.304 |
| Ocular | 7 (4.6) | 6 (3.9) | 1.17 (0.39, 3.58) | 0.777 |
| Hematologic | 3 (2.0) | 4 (2.6) | 0.75 (0.16, 3.39) | 1.000a |
| Cardiac | 4 (2.6) | 2 (1.3) | 2.03 (0.37, 11.23) | 0.684a |
| Endocrine | 5 (3.3) | 1 (0.7) | 5.14 (0.59, 44.48) | 0.214a |
| Pituitary | 5 (3.3) | 0 | — | 0.061a |
| Renal | 4 (2.6) | 0 | — | 0.123a |
aFisher’s exact test.
Abbreviations: IQR: interquartile range; irAEs: immune-related adverse events.